Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain European Union (EU) territories, Lupin said in a statement.Lupin inks distribution pact with 3 firms to commercialise NaMuscla in Europe
Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain European Union (EU) territories, Lupin said in a statement.
Subscribe to:
Post Comments (Atom)
-
Thirteen tier 2 and 3 cities register higher traffic in December than pre-COVID-19 levels.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
No comments:
Post a Comment